Document is current
Any future updates will be listed below
-
Authors
Nanki, Toshihiro https://orcid.org/0000-0002-3482-074X
Yamaguchi, Tomohiro
Umetsu, Kosei
Tanabe, Ryunosuke
Maeda, Naoki
Kanazawa, Minori
Furuno, Yuko
Matsuda, Shinichi
Takemoto, Shinya
Asao, Keiko
Kamiuchi, Tatsuya
- License Information
-
More Information
Article History
Received: 27 September 2024
Revised: 13 December 2024
Accepted: 9 January 2025
First Online: 7 February 2025
Compliance with ethical standards
:
: The study was conducted in accordance with the Declaration of Helsinki [] and with the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Ethical approval was obtained from the Non-Profit Organisation MINS Research Ethics Committee on 11th January 2023 (MINS-REC-230201). The MDV database was anonymized; thus, informed consent was not obtained from the study participants. The transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines was followed [].
: Toshihiro Nanki received grant/research support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Ayumi Pharmaceutical Corp, Nippon Kayaku Co., Ltd., AbbVie GK, Sanofi K.K., Teijin Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., UCB Japan Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.; consultant fees from UCB Japan Co., Ltd., Eisai Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and speakers fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Mylan N.V., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., UCB Japan Co. Ltd., Nippon Kayaku Co., Ltd., Sanofi K.K., Teijin Pharma Ltd., Gilead Sciences, Inc., and Taisho Pharmaceutical Co., Ltd. Tomohiro Yamaguchi, Kosei Umetsu, Ryunosuke Tanabe, Naoki Maeda, Minori Kanazawa, Yuko Furuno, Shinichi Matsuda, Shinya Takemoto, and Tatsuya Kamiuchi are employees of Chugai Pharmaceutical Co. Ltd. Keiko Asao was an employee of IQVIA Solutions Japan G.K. at the time of study conduct and is currently the president and shareholder of Kappa Medical K.K.
